Journal article
Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial
Jennifer E Thorne, Elizabeth A Sugar, Janet T Holbrook, Alyce E Burke, Michael M Altaweel, Albert T Vitale, Nisha R Acharya, John H Kempen, Douglas A Jabs, Glenn J Jaffe, Christina F Bunn, LaToya Greene, Dilraj Grewal, Sean Grout, Michael Hughes, Ryan Imperio, Michael P Kelly, Brian Lutman, Paola Perez, Steven Yeh Show all
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2019
Abstract
PURPOSE: To evaluate the comparative effectiveness of 3 regional corticosteroid injections for uveitic macular edema (ME): periocular triamcinolone acetonide (PTA), intravitreal triamcinolone acetonide (ITA), and the intravitreal dexamethasone implant (IDI). DESIGN: Multicenter, randomized clinical trial. PARTICIPANTS: Patients with uveitic ME. METHODS: Patients were randomized 1:1:1 to receive 1 of the 3 therapies. Patients with bilateral ME were assigned the same treatment for both eyes. MAIN OUTCOME MEASURES: The primary outcome was the proportion of baseline (PropBL) central subfield thickness (CST) at 8 weeks (CST at 8 weeks/CST at baseline) assessed with OCT by masked readers. Secondar..
View full abstractGrants
Awarded by National Eye Institute, National Institutes of Health
Funding Acknowledgements
This study is a multicenter clinic trial supported by collaborative agreements from the National Eye Institute, National Institutes of Health (D.A.J.: U10EY024526, J.T.H.: U10EY024527, M.M.A.: U10EY024531). Allergan (Irvine, CA) donated a limited supply of dexamethasone implants for participants who could not obtain them otherwise. A representative of the National Eye Institute participated in the oversight of the study and review of the manuscript but not directly in the study design, data collection, analysis, and interpretation of the data, or in the preparation of this manuscript.